The effect of protein binding on antibiotic efficacy is controversial. The pharmacologic effect of an antibiotic is believed to be related to its unbound concentration at the site of infection. It is unknown whether antibiotics with a low degree of serum protein binding are clinically superior to antibiotics that are highly protein bound. In a randomized, crossover investigation, the serum bactericidal activities of a single dose of ceftazidime (30 mg/kg) and cefoperazone (30 mg/kg) were studied in six healthy volunteers against three clinical isolates of Pseudomonas aeruginosa for which both antibiotics had similar MICs and MBCs. Serum samples were collected over 12 h. The total and unbound antibiotic concentrations were determined by high-pressure liquid chromatography. Mean peak total concentrations of ceftazidime and cefoperazone in serum were 101.7 ± 18.6 and 264.1 149.6 ,ug/ml, respectively. Due to its lower protein binding (21 ± 6%), ceftazidime had significantly higher unbound concentrations in serum than did the highly bound cefoperazone (91.5 ± 2%). Mean peak unbound concentrations were 78.5 ± 12.5 and 24.2 ± 17.8 ,ug/nl for ceftazidime and cefoperazone, respectively. The unbound concentration of ceftazidime at each sampling time was higher than that of cefoperazone. Although total concentrations were consistently higher than the MICs, serum containing cefoperazone showed minimal bactericidal activity against the isolates. In contrast, despite lower total concentrations, ceftazidime had greater antibacterial activity than cefoperazone. Serum bactericidal activity was more closely related to unbound rather than total antibiotic concentrations. Our data support the concept that only the unbound drug is microbiologically active.
The clinical significance of serum protein binding on the distribution, elimination, and microbiological activity of antibiotics is controversial (2, 4, 7, 11, 14-16, 18, 20, 21, 24, 26-28) . Pharmacological action depends on the capability of a drug to bind to its target receptors in tissue. The unbound drug rather than the protein-bound drug is presumed to be biologically active. The extent of serum protein binding is a function of the affinity between the drug and the protein, the concentrations of protein and drug in the serum, and the number of binding sites on the protein (23) .
Chambers et al. reported treatment failures with cefonicid in patients with endocarditis due to Staphylococcus aureus (6). The MIC determined in broth diluent for the clinical isolates was well below achievable cefonicid concentrations in serum. However, little serum bactericidal activity was observed, and breakthrough bacteremia occurred in three of the four patients treated. The authors suggest that the failure was probably due to the high degree of protein binding of cefonicid (up to 98%) and, therefore, the small amount of unbound drug present in the serum.
In the presence of serum, highly protein bound antibiotics generally have less antimicrobial activity in vitro; this is related to the reduced amount of unbound antibiotic (12, 13, 19, 22) . On the other hand, the diluent used in the determination of the MIC is broth, which contains no internal standard used was ticarcillin. For both assays, the mobile phase was filtered through a Millipore membrane filter before use. Column elution was carried out with a flow rate of 1 m/min and a pressure of 1,500 lb/in2. The effluent was monitored by UV absorbance at 254 nm. Standards of known ceftazidime or cefoperazone concentrations were made up in pooled human serum to give concentrations ranging from 0.5 to 50 and from 0.5 to 100 ,ug/ml, respectively. Serum protein precipitation was performed by mixing the sample with acetonitrile containing the internal standard.
The supernatant (15 RI) was injected directly onto the column. The sensitivity limit for both assays was 0.5 jig/ml.
Reproducibility measurements yielded interday and intraday variability of less than 10%.
Pharmacokinetic analysis. The pharmacokinetic parameters of both antibiotics were estimated by noncompartmental methods. The area under the serum concentration-time curve (AUC) for total and unbound antibiotic (AUCtOtal and AUCunbound, respectively) was determined by the log trapezoidal rule and extrapolated to infinity by dividing the last measured serum concentration value by kel. ke, is the terminal elimination rate constant estimated by using at least the last three data points on the terminal log-linear phase of the serum concentration-time curve. Half-life was calculated by dividing the natural logarithm of 2 by kel. The SBA. Three different isolates of Pseudomonas aeruginosa for which ceftazidime and cefoperazone MICs and MBCs were similar were selected from clinical specimens at the University of California Hospitals. The MIC of ceftazidime for all three isolates was 2 ,ug/ml, in contrast to 4 to 8 ,ug/ml for cefoperazone. The MBC of ceftazidime for the same isolates was 8 to 16 ,ug/ml, compared with 16 ,ug/ml for all isolates for cefoperazone. The bactericidal activity of serum samples at each collection time was determined in triplicate by a microdilution technique (17 ,u.g/ml, and the mean total concentrations in serum 8 h after the dose were 7.5 ± 3.8 and 4.2 ± 1.9 jig/ml.
The mean protein binding of ceftazidime and cefoperazone was 21.0 ± 6.0% and 91.5 ± 2.0%, respectively. At each sampling time, the unbound concentration of ceftazidime was higher than that for cefoperazone. The mean unbound concentration of ceftazidime 30 min after the end of infusion was 78.5 ,ug/ml, compared with 24.2 ,ug/ml for cefoperazone. At 8 h after the dose, the mean unbound concentrations of ceftazidime and cefoperazone were 3.3 ± 1.7 and 0.7 ± 0.2 ,ug/ml, respectively.
There was a significant difference in the clearance of unbound drug: 70 theless, the SBAs of ceftazidime and cefoperazone against the same clinical isolates varied markedly. Serum taken before administration of antibiotic was not bactericidal against any isolates. There was minimal SBA observed with cefoperazone against all the three isolates, even at peak serum concentrations. In contrast, the SBA of ceftazidime against the same three isolates was .1:8 in approximately 60% of samples at peak serum concentration. The duration of detectable SBA was also longer for ceftazidime after dosage administration. Mean unbound ceftazidime concentrations were above both the MIC and MBC for the three clinical isolates for 4 to 6 h as compared with less than 1 h for cefoperazone.
The reciprocals of the mean serum bactericidal titerversus-time curves for ceftazidime and cefoperazone for the three isolates of P. aeruginosa are shown in Fig. 2 . As a result of the minimal bactericidal activity, the AUBC of cefoperazone was negligible for all three clinical isolates. The AUBC for ceftazidime against each strain of P. aeruginosa was significantly greater than that of cefoperazone (P < 0.05). In plotting AUCunbOund versus AUBC, greater bactericidal activity was observed with ceftazidime compared with cefoperazone (Fig. 3) . Ceftazidime had greater killing activity as a result of higher AUCunbound. The minimal AUCunbOund achieved with comparable dosage of cefoperazone was associated with much less killing activity. There 
